These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2126 related articles for article (PubMed ID: 24845343)

  • 1. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
    Fei F; Jariwala A; Pullarkat S; Loo E; Liu Y; Tizro P; Ali H; Otoukesh S; Amanam I; Artz A; Ally F; Telatar M; Nakamura R; Marcucci G; Afkhami M
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.
    Rumi E; Harutyunyan A; Elena C; Pietra D; Klampfl T; Bagienski K; Berg T; Casetti I; Pascutto C; Passamonti F; Kralovics R; Cazzola M
    Am J Hematol; 2011 Dec; 86(12):974-9. PubMed ID: 21953568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphism array-based karyotyping in acute myeloid leukemia or myelodysplastic syndrome with trisomy 8 as the sole chromosomal abnormality.
    Hahm C; Mun YC; Seong CM; Han SH; Chung WS; Huh J
    Acta Haematol; 2013; 129(3):154-8. PubMed ID: 23208021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
    Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
    Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome.
    da Silva FB; Machado-Neto JA; Bertini VHLL; Velloso EDRP; Ratis CA; Calado RT; Simões BP; Rego EM; Traina F
    J Clin Pathol; 2017 May; 70(5):435-442. PubMed ID: 27836923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes.
    Qin Y; Zhang H; Feng L; Wei H; Wu Y; Jiang C; Xu Z; Zhu H; Liu T
    Ann Med; 2022 Dec; 54(1):2627-2636. PubMed ID: 36148999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
    Faria C; Tzankov A
    Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
    Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
    Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.
    Kanagal-Shamanna R; Hodge JC; Tucker T; Shetty S; Yenamandra A; Dixon-McIver A; Bryke C; Huxley E; Lennon PA; Raca G; Xu X; Jeffries S; Quintero-Rivera F; Greipp PT; Slovak ML; Iqbal MA; Fang M
    Cancer Genet; 2018 Dec; 228-229():197-217. PubMed ID: 30377088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
    Talati C; Padron E
    Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD.
    Gondek LP; Dunbar AJ; Szpurka H; McDevitt MA; Maciejewski JP
    PLoS One; 2007 Nov; 2(11):e1225. PubMed ID: 18030353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 107.